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Abstract
Purpose Lutein and zeaxanthin are macular pigments
with a protective function in the retina. These xanthophylls
must be obtained from the diet or added to foods or sup-
plements via easy-to-use, stable formulations. The tech-
nique employed to produce these formulations may affect
the bioavailability of the xanthophylls.
Methods Forty-eight healthy volunteers were randomized
into this double-blind, cross-over study investigating the
plasma kinetics of lutein provided as two different beadlet
formulations. Subjects (n = 48) received a single dose
of 20 mg of lutein as either a starch-matrix (‘‘SMB’’,
FloraGLO Lutein 5 %) or as a cross-linked alginate-
matrix beadlet (‘‘AMB’’, Lyc-O-Lutein 20 %) formulation.
Plasma concentrations of lutein and zeaxanthin were
measured at 0, 1, 3, 6, 9, 12, 14, 24, 26, 28, 32, 36, 48, 72,
168, and 672 h.
Results The mean plasma AUC(0–72h), AUC(0–672h), and
Cmax for total lutein and zeaxanthin and their all-E-isomers
were significantly increased (p \ 0.001) from pre-dose
concentrations in response to SMB and AMB. There was
no difference in lutein Tmax between the two test articles.
However, by 14 h post-dose, total plasma lutein increased
by 7 % with AMB and by 126 % with SMB. Total lutein
AUC(0–72h) and AUC(0–672h) were 1.8-fold and 1.3-fold
higher, respectively, for SMB compared to AMB. Both
formulations were well tolerated by subjects in this study.
Conclusion These findings confirm that the bioavailability
of lutein and zeaxanthin critically depends on the formula-
tion used and document a superiority of the starch-based
over the alginate-based product in this study.
Keywords Xanthophylls  Carotenoids  Lutein 
Zeaxanthin  all-E-lutein  Bioavailability
Introduction
Lutein and zeaxanthin are xanthophyllic carotenoids found
in fruits and vegetables and have been described as natural
antioxidants [1, 2]. Humans are not capable of synthesizing
carotenoids, and thus, their presence in human tissues is
entirely of dietary origin [3]. On average, the combined
daily dietary intake of lutein plus zeaxanthin ranges around
2 mg for the US population [4] but for some populations,
such as South Pacific islanders, it may be as high as 26 mg
per day due to their unusually high intake of fruits and
vegetables high in these carotenoids [5]. Lutein is found in
a number of human tissues including serum (0.1–1.23 lM),
liver (0.1–3.0 lM), kidney (0.037–2.1 lM), and lung
(0.1–2.3 lM) [6]. By far the highest concentration of these
carotenoids (0.1–1 mM) is found in the human retina [7]
providing evidence for active uptake or storage [8]. The
macular region of the retina is yellow as a result of the
presence of lutein and zeaxanthin [3]. Their specific loca-
tion and physiochemical properties including their ability
to absorb high-energy blue light and their capability to
quench reactive oxygen species suggest that these
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carotenoids serve a protective function in the retina [9].
Previous studies showed that poor dietary intake or low
plasma lutein and zeaxanthin concentrations are associated
with low macular pigment density and an increased risk
potential for age-related macular degeneration (AMD), an
irreversible ocular condition that is the major cause of
blindness in the elderly [10].
Although individual responses are known to differ
markedly, many other factors could also play important
roles during intestinal absorption, metabolism, and serum
clearance of carotenoids, including interaction with other
carotenoids [11]. Due to the solubility characteristics of
carotenoids, the amount of fat consumed in conjunction
with carotenoids appears to be an important factor in
determining their bioavailability [12, 13].
In one of the most rigorous studies conducted previ-
ously, Thu¨rmann et al. [14] showed that supplementation
with 4.1 and 20.5 mg unesterified lutein increased plasma
lutein concentrations approximately 3.5- and 10-fold,
respectively. On the basis of previous studies, it may be
hypothesized that dietary lutein and zeaxanthin in the form
of lutein-containing supplements may increase the amount
of serum lutein significantly upon the ingestion of lutein
capsules [15]. As lutein in its crystalline form is unac-
ceptable for use in tableted products for a variety of rea-
sons, it is important to encapsulate the lutein into a
powdered form. However, not all encapsulation materials
that could be used in creating a powdered form are equally
acceptable. For instance, one of the most common mate-
rials, bovine-derived gelatin, is infrequently used because
of reasons associated with bovine spongiform encephalitis.
Additionally, manufacturers of vitamins/dietary supple-
ments require encapsulated materials that can withstand a
wide range of tableting pressures placing significant
restrictions upon the materials that can be used in the
encapsulation of lutein and zeaxanthin. These same
restrictions are believed to play a critical role in the bio-
availability of these xanthophylls since the encapsulation
must release these molecules during the digestive process
in order for these carotenoids to reach the bloodstream.
While several single-dose, comparative pharmacokinetic
(PK) studies have been conducted in human subjects using
lutein or lutein esters [11–13], only one multiple-dose PK
study [14] has been published. No comparative PK studies
using two different sources of unesterified lutein have been
published so far. Unpublished data indicated that materials
and processes used in the encapsulation of lutein may
affect lutein bioavailability. The present study was
designed to compare, in human subjects, the bioavailability
of lutein and zeaxanthin when ingested in two different
formulations. Data gathered from Thu¨rmann et al. [14] and
other sources were used to establish many of the parame-
ters used to design this study, including (but not limited to)
the use of a single dose, the duration of the follow-up after
lutein/zeaxanthin dosage administration, and the number of
subjects employed.
Subjects
Forty-eight subjects (24 males and 24 females) were
recruited into the study from an available clinic volunteer
database. To be eligible for enrollment, subjects were
required to be healthy as confirmed by screening laboratory
results, medical history, and physical examination, be
between 18 and 65 years of age, have a BMI [20 and
\30 kg/m2, have screening plasma lutein concentrations
between 0.12 and 0.49 lmol/L, and agree to maintain current
dietary habits throughout the duration of the study. Subjects
using cholesterol lowering medications, supplements con-
taining lutein or beta-carotene, medications that could affect
drug or dietary supplement metabolism and excretion of
drugs or dietary supplements, other natural health products
including vitamins and minerals, or having an allergy or
sensitivity to study supplement ingredients were excluded.
This study was reviewed by the Natural Health Products
Directorate (NHPD), Health Canada, Ottawa, Ontario,
Canada, and the Institutional Review Board Services
(IRBS), Aurora, Ontario, Canada, and was unconditionally
approved by the NHPD, and IRBS on July 30, 2009, and
August 18, 2009, respectively.
This study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and its subsequent
amendments. Informed consent was obtained from each
subject at the screening visit prior to any study-related
activities.
Study design
The study was a single-center, randomized, double-blind,
cross-over, 672-h bioavailability clinical investigation
conducted at KGK Synergize Inc., London, Ontario, Can-
ada. The study consisted of a two-day baseline period
followed by a single-dose bioavailability phase that was
followed by a second single-dose bioavailability phase
28 days later. This 28-day separation of the two phases was
considered appropriate, since after 25 days plasma lutein
levels are expected to have dropped to approximately 3 %
of peak concentrations based on a terminal elimination
half-life of 5 days as reported by Thu¨rmann et al. [14].
At screening, informed consent was obtained and a
medical history and concomitant therapies were reviewed.
Height, weight, heart rate, and blood pressure were mea-
sured and BMI was calculated. A physical examination was
performed and peripheral blood collected to determine
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complete blood count (CBC), electrolytes, glucose, creat-
inine, aspartate aminotransferase (AST), alanine amino-
transferase (ALT), gamma glutamyltransferase (GGT),
bilirubin, and lutein. Eligible subjects returned to the clinic
for their baseline visits. At baseline (day -2 and day -1),
concomitant therapies were reviewed, and fasting (12 h)
blood samples were collected for analyses of plasma lutein
and zeaxanthin.
At the start of the bioavailability Phase I (day 0), a
fasting (12 h) blood sample was collected for pre-dose
lutein and zeaxanthin analysis. The subject was then given
a single AMB or SMB capsule (Time = 0 h) with
breakfast provided immediately afterward (AMB capsules
contained 20.9 mg lutein (2.2 % coefficient of variation,
CV) and 1.55 mg zeaxanthin (2.3 % CV) per dose and
SMB capsules contained 20.4 mg lutein (1.5 % CV) and
1.75 mg zeaxanthin (1.5 % CV) per dose). This capsule
was taken orally by test subjects in the morning and
witnessed by the study coordinator thereby ensuring
compliance. Thereafter, blood samples were collected at 1,
3, 6, 9, 12, 14, 24, 26, 28, 32, 36, 48, 72, 168, and 672 h
post-dose. All subjects received lunch following the 6-h
sample and dinner after the 12-h sample. Subjects
remained in the clinic from pre-dose until the 14-h sample
collection; returned to the clinic fasting on day 1 for 24,
26, 28, 32, and 36 h post-dose blood collections and
remained in the clinic for that period of time. Breakfast
was provided immediately after the 24-h blood draw,
lunch following the 28-h sample and dinner immediately
following the 32-h sampling. Light snacks were provided
between dinner and 36 h post-dose sampling. The food
consumed at each meal time including all snacks were
measured and recorded. The meals provided to subjects in
the clinic during the first 36 h of the bioavailability phases
did not include foods considered to be high in xanthophyll
content. Subjects were permitted to leave the clinic after
the 36 h post-dose blood sample. Subjects returned fasting
(12 h) to the clinic for the 48, 72, and 168 h post-dose
collections. Adverse events and concomitant therapies
were reviewed at every visit.
Subjects returned to the clinic fasting (12-h fast) on the
28th day for Phase II of the study. The Phase II pre-dose
(Time = 0 h) blood sample was the same as the 672-h
Phase I post-dose sample. During this visit, adverse events
and concomitant therapies were again reviewed. The sub-
jects received one capsule of the second test article and all
blood sampling and procedures remained exactly the same
as in Phase I. The six meals and the snacks provided during
the initial 36 h of the second bioavailability phase were of
the same composition and amount as the meals provided
during the first bioavailability phase. Subjects were not
provided with caffeinated beverages during the first 36 h of
either bioavailability phase.
Sample size
A sample size calculation was performed based on the plasma
lutein area under the curve [14]. Assuming a type I error rate
(two-sided) of 0.05, an estimated standard deviation of 15.0, a
correlation of 0.10 between the two study phases, and a 15 %
loss to follow-up, 48 subjects were required to detect a
between-formulation difference of 9.0 lmol h/L in the area
under the curve for plasma lutein [16].
Randomization
Enrolled subjects were stratified by gender to balance the
two dosing sequences thus ensuring that an equal number
of males and females were assigned to each sequence
group (12 males and 12 females per dosing sequence).
Subjects were randomized to one of two treatment
sequences (AMB to SMB or SMB to AMB) in blocks of
two. The Investigator was provided with two randomiza-
tion schedules, one for males and one for females.
Blinding
The test articles were labeled with the randomization number
and order of treatment, that is, first dose and second dose,
thereby blinding the identity of the test articles to the subject,
the Investigator and all clinical site personnel directly
involved in this study. The Investigator received sealed code
envelopes for each subject enrolled into the study identifying
which dosing sequence the subject received. A broken code
required the patient to be withdrawn from the study. No
premature unblinding occurred during the study.
Lutein and zeaxanthin analysis
Plasma lutein and zeaxanthin measurements were per-
formed at DSM’s Analytical Research Center (Kaiseraugst,
Switzerland). Their concentrations were determined by
normal-phase high-performance liquid chromatography,
using published procedures [17]. Plasma samples were
analyzed for zeaxanthin (all-E and total (=sum of all-E and
Z-isomers)) and lutein (all-E and total (=sum of all-E and
Z-isomers)). The xanthophylls were extracted from plasma
(100 lL) with a 20 % mixture of n-hexane and chloroform
(1,100 lL) after dilution with water (100 lL) and protein
precipitation with ethanol (200 lL). After centrifugation,
an aliquot (800 lL) of the clear supernatant fluid was dried
under nitrogen at room temperature. The dried residue was
quantitatively redissolved in the mobile phase (200 mL n-
hexane and acetone; 19 %, by volume). The resulting
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solution was injected (100 lL) into a normal-phase HPLC
system (Jasco, Japan) equipped with an autosampler
(15 C), a column oven (40 C), an HPLC pump, and an
ultraviolet–visible detector. Data acquisition, integration,
and quantification were performed with Atlas Software
(Thermo Labsystems). Quantification was performed by
applying external calibration, without using internal
standards. The separation was done on a polar column
(Lichrosorb, Si60, 5 mm, 250 9 4 mm; Stagroma, Swit-
zerland) with a mixture of n-hexane and acetone (19 %, by
volume) at a flow rate of 1 mL/min. Xanthophylls were
detected at a wavelength of 452 nm. The identification of
the compounds was carried out by comparing the retention
times with those of authentic reference standards of lutein
and zeaxanthin (DSM Nutritional Products, Switzerland).
To assess the daily and long-term laboratory performance
of the HPLC plasma analytics, dedicated control plasma
was used. The control plasma samples were analyzed at
least 4 times/day during the study as described in [17]. In
addition, the method was regularly checked for accuracy
and precision (±15 %) by participation in inter-laboratory
studies organized by the National Institute of Standard and
Technologies (NIST, Gaithersburg, Maryland, US). The
limit of detection (LOD) for lutein, zeaxanthin and their
isomers was 0.002 lmol/L, and the lower limit of quanti-
fication (LLQ) for lutein, zeaxanthin and their isomers was
0.007 lmol/L.
Test articles
The two test articles investigated in this study were Lyc-O-
Lutein 20 % VBAF, an alginate-matrix beadlet formulation
(‘‘AMB’’, LYCORED, Beer Sheva, Israel), and FloraGLO
Lutein 5 % CWS-S/TG, a starch-matrix beadlet formula-
tion (‘‘SMB’’, DSM Nutritional Products, Kaiseraugst,
Switzerland). The test articles were filled into gelatin cap-
sules opacified with titanium oxide and colored with red iron
oxide by Temmler Werke, Munich, Germany. The AMB
lutein beadlet material contained 203 mg/g of lutein and
15.3 mg/g of zeaxanthin. The respective capsules were
accordingly filled with 98.5 mg of beadlets to contain
exactly 20.9 mg of lutein and 1.55 mg zeaxanthin per cap-
sule. This test article contained unesterified lutein in a cross-
linked alginate-based formulation. The SMB lutein beadlet
material contained 51 mg/g of lutein and 4.35 mg/g of
zeaxanthin. The respective capsules were accordingly filled
with 392.2 mg of these beadlets to contain exactly 20.4 mg
of lutein and 1.75 mg zeaxanthin per capsule. This test
article contained unesterified lutein in a starch-based matrix.
Both test articles were assayed for lutein content and content
uniformity by HPLC before initiation of the study and found
to be acceptable.
Statistical methods
The primary study endpoint was the 72-hour area under the
curve for plasma lutein (AUC0-72h). Secondary endpoints
included the maximum concentration (Cmax), the time at
which the maximum concentration was observed for
plasma lutein (Tmax) and AUC extended to include 672-h
plasma concentrations, and finally the 72- and 672-h
pharmacokinetic parameters (AUC0-72h, AUC0–672h, Cmax,
and Tmax) for zeaxanthin. The area under the curve was
calculated using the linear trapezoidal rule. In order to meet
the assumption of normality, statistics on AUC and Cmax
were based on log transformed values for individual sub-
jects [18]. One subject withdrew prior to the 672-h blood
collection in their first dosing period (SMB). This subjects’
672-h values were imputed using the subjects pre-dose
values (time = 0 h) for the missing data point. The pre-
dose values were used as it was expected that the plasma
lutein and zeaxanthin concentrations would reach pre-dose
levels after 672 h. This subject was included in the analysis
of the 672-h bioavailability for SMB.
Descriptive statistics (mean and standard deviation) are
reported for both test articles. Repeated measures analysis
of variance was used to compare the two test articles.
Subjects withdrawn prior to the second dosing period were
excluded from the repeated measures analysis of variance.
Tests for carry-over (between-sequence) and period effects
were conducted [18]. Where values were reported as less
than the lower limit of detection (LOD) or the lower limit
of quantification (LLQ), a random value between 0 and the
LLQ or LOD was assigned using SAS for the particular
analyte being assessed. Adverse events which occurred
within the study period were reported in detail, and the
percentage of subjects experiencing adverse events were
compared between the test articles using the Mainland–
Gart test [18]. Probability values less than 0.05 denote
statistically significant differences between test articles.
SAS version 9.1 (Cary, NC, USA) was used to perform the
statistical analysis.
Results
A total of 48 subjects (24 males and 24 females) were
randomized to participate in the study. One subject with-
drew due to personal reasons after the 168-h time point of
the first dosing period and thus did not participate in the
second dosing period (Fig. 1). Subjects presented with a
mean age of 38.5 ± 14.0 years and mean BMI of
25.6 ± 3.3 kg/m2 (Table 1). After the initial washout
period prior to the first treatment (day -1), subjects had
a total lutein and total zeaxanthin plasma concentra-
tion of 0.198 ± 0.086 lmol/L and 0.067 ± 0.036 lmol/L,
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respectively, representing a lutein to zeaxanthin ratio of
3:1. No carry-over or period effects were observed for any
of the results obtained from this study.
Lutein bioavailability
The mean plasma total lutein and all-E-lutein Cmax,
AUC(0–72h) and AUC(0–672h) were significantly higher
(p \ 0.001) compared to baseline for each of the two test
products. However, the response to SMB was also signif-
icantly different from AMB with SMB being more bio-
available (Tables 2, 3). Though the time to reach maximum
concentration (Tmax) was not significantly different for total
lutein or all-E-lutein between the two test articles during
the first 72 h (Table 2), Tmax occurred sooner in response to
SMB for total lutein and all-E-lutein as compared to AMB
(17.6 vs. 20.6 h and 17.4 vs. 19.8 h, respectively).
The mean plasma profile of all-E-lutein (0–72 h and
0–672 h) followed a comparable pattern to the mean
plasma profile of total lutein for both test articles (Figs. 2,
3). The mean increase in plasma for total lutein and all-E-
lutein concentrations from 0 (pre-dose) to 14 h after
administration of AMB was 0.013 lmol/L (7.1 %) and
0.011 lmol/L (7.1 %), respectively. The mean increase in
plasma total lutein and all-E-lutein concentrations from 0
(pre-dose) to 14 h after administration of SMB was
0.228 lmol/L (126.0 %) and 0.219 lmol/L (144.1 %),
respectively.
At 72 h post-administration (Fig. 2) of SMB, all-E-
lutein remained higher than pre-dose concentrations
(D = 0.100 lmol/L or 65.4 %). However, when subjects
were on AMB, mean plasma all-E-lutein concentrations
reached pre-dose concentrations (D = -0.003 lmol/L or
-1.9 %) by 72 h. Total plasma lutein showed similar
results.
By 672 h (Fig. 3), plasma all-E-lutein concentrations
remained higher than pre-dose (D = 0.017 lmol/L or
11.1 %) for SMB and remained similar to pre-dose con-
centrations (D = 0.002 lmol/L or 1.3 %) for AMB.
Changes in plasma total lutein concentrations followed a
similar pattern to plasma all-E-lutein at 672 h.
Zeaxanthin bioavailability
Mean increases from baseline in plasma total zeaxanthin
and all-E-zeaxanthin Cmax were significantly higher
(p \ 0.01) in response to SMB as compared to AMB
(Table 2). The difference in zeaxanthin dose between
AMB (1.55 mg) and SMB (1.75 mg) was accounted for in
the calculations for Tables 2 and 3. Tmax was not
Subjects Screened 
n = 76 
Ineligible  (n = 28) 
Did not meet inclusion criteria   (n = 15) 
Withdrew Consent    (n = 1) 
Enrollment filled/closed   (n = 12)
Random Assignment 
n = 48 
Total number of subjects included in statistical comparisons of 
primary and secondary endpoints: n = 47 
Total number of subjects included in safety analysis: n = 48 
Completed first phase 
n = 24 
Allocated to Sequence: 
SMB  AMB 
n = 24 
Completed first phase 
n = 23 
(1 subject withdrew prior to 
672h blood collection)
Completed second phase 
n = 24 
Completed second phase 
n= 23 
Allocated to Sequence: 
AMB  SMB 
n = 24 
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statistically significant between groups. Plasma total zea-
xanthin and all-E-zeaxanthin AUC(0-72h) and AUC(0-672h)
were not different between treatments.
The mean plasma profile of all-E-zeaxanthin (0–72 h
and 0–672 h) followed a comparable pattern to the mean
plasma profile of total zeaxanthin for both test articles
(Figs. 4, 5). The mean increase in plasma total zeaxanthin
and all-E-zeaxanthin concentrations from 0 (pre-dose) to
14 h after administration of AMB was 0.003 lmol/L
(5.1 %) and 0.003 lmol/L (6.4 %), respectively. The mean
increase in plasma total zeaxanthin and all-E- zeaxanthin
concentrations from 0 (pre-dose) to 14 h after administration
of SMB was 0.008 lmol/L (12.9 %) and 0.008 lmol/L
(16.3 %), respectively (Table 2).
Seventy-two hours post-administration (Figs. 4, 5) of
AMB, mean plasma total zeaxanthin and all-E-zeaxanthin
concentrations were decreased to lower levels than
those seen pre-dose (D = -0.003 lmol/L or -5.1 % and
D = -0.002 lmol/L or -4.3 %, respectively). For SMB,
though values had reduced from peak plasma concentrations,
total plasma zeaxanthin concentrations remained higher than
pre-dose concentrations (D = 0.003 lmol/L or 4.8 %) and
plasma all-E-zeaxanthin concentrations remained higher
than pre-dose concentrations (D = 0.003 lmol/L or 6.1 %)
72 h post-administration (Fig. 4).
It is noteworthy that mean plasma total zeaxanthin and
mean plasma all-E-zeaxanthin concentrations were below
pre-dose concentrations at 24, 26, 28, 32, 36, 48, and 72 h
post-administration of AMB. This pattern was not seen for
SMB, where values remained above pre-dose concentra-
tions during the same period. The mean drop below pre-
dose concentrations reported for AMB from the 24 through
72 h blood collections ranged between -0.002 and
-0.006 lmol/L (-3.4 to -10.2 %) for total zeaxanthin
and between -0.002 and -0.005 lmol/L (-4.2 to -10.6 %)
for all-E-zeaxanthin.
Adverse events
A total of 27 adverse events were reported during the study
(13 for AMB and 14 for SMB). Only one of these adverse
events was categorized by the Investigator as being related
to the test article, specifically to SMB. This event, a loose
bowel movement, occurred on the day the test article was
administered and resolved the following day without the
need for concomitant medication.
Discussion
Previous studies have been conducted using multiple dos-
ing regimens and variable doses to determine the plateau
concentration of lutein in the bloodstream. The current
study was designed to assess the effect of different for-
mulation technologies on the bioavailability profile of
lutein and zeaxanthin after single oral doses of two com-
parative test articles both of which contained lutein and
zeaxanthin, specifically in a starch-based or in an alginate-
based matrix.
SMB demonstrated greater bioavailability than AMB
exhibiting a 126.0 % increase at 14 h in total lutein and a
144.1 % increase from pre-dose in its principle isomer
all-E-lutein while AMB showed an 7.1 % increase in total
lutein and a 7.1 % increase from pre-dose in all-E-lutein.
Seventy-two hours post-administration, the plasma con-
centrations of total lutein and all-E-lutein remained
approximately 65 % higher than pre-dose values for SMB,
whereas plasma values were at or below pre-dose con-
centrations for AMB by 72 h.
Although to a much lower degree due to the lower dose,
zeaxanthin plasma profiles were similar to those of lutein,
SMB performed better than AMB with a 12.9 % increase at
Table 1 Demographics and characteristics of all randomized sub-
jects at baseline
All subjects (n = 48)
Age (years)a 38.5 ± 14.0
BMI (kg/m2)a 25.6 ± 3.3
Mean systolic BP (mm Hg)a 112.1 ± 10.7
Mean diastolic BP (mmHg)a 70.1 ± 7.7
Mean heart rate (bpm)a 72.5 ± 7.7
Luteina
Total lutein (lmol/L) 0.198 ± 0.086
all-E-lutein (lmol/L) 0.166 ± 0.071
Zeaxanthina
Total zeaxanthin (lmol/L) 0.067 ± 0.036
all-E-zeaxanthin (lmol/L) 0.052 ± 0.026
Gender—femaleb 24 (50.0 %)
Race/ethnicityb
Asian-oriental 2 (4.2 %)
Black 2 (4.2 %)
Caucasian 42 (87.5 %)
East Indian 2 (4.2 %)
Alcohol useb
Daily/weekly 13 (27.1 %)
None 7 (14.6 %)
Occasional 28 (58.3 %)
Tobacco useb
Current 7 (14.6 %)
Former 14 (29.2 %)
Never 27 (56.3 %)
a Continuous variables are displayed as mean with standard deviation
b Categorical variables are displayed as n (%)
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Table 2 Lutein and zeaxanthin bioavailability measured by the response of plasma concentrations over 72 h after a single dose of AMB or SMB
AMB (n = 47) p valuea SMB (n = 48) p valuea p valueb
Total lutein
Dose (mg) 20.9 20.4
Cmax (lmol/L)
c 0.238 ± 0.091 \0.001 0.460 ± 0.169 \0.001 \0.001
Cmax (increase from t = 0 h) (lmol/L) 0.055 ± 0.054 \0.001 0.279 ± 0.130 \0.001 \0.001
Tmax (h) 20.6 ± 22.5 \0.001 17.6 ± 7.8 \0.001 0.432
C14h (increase from t = 0 h) (lmol/L) 0.013 ± 0.046 0.059 0.228 ± 0.154 \0.001 \0.001
AUC(0–72h) (lmol h/L)
c 13.032 ± 4.847 \0.001 23.508 ± 8.539 \0.001 \0.001
all-E-lutein
Cmax (lmol/L)
c 0.200 ± 0.077 \0.001 0.416 ± 0.157 \0.001 \0.001
Cmax (increase from t = 0 h) (lmol/L) 0.046 ± 0.047 \0.001 0.264 ± 0.124 \0.001 \0.001
Tmax (h) 19.8 ± 21.1 \0.001 17.4 ± 7.5 \0.001 0.498
C14h (increase from t = 0 h) (lmol/L) 0.011 ± 0.039 0.056 0.219 ± 0.143 \0.001 \0.001
AUC(0–72h) (lmol h/L)
c 10.965 ± 4.040 \0.001 20.801 ± 7.874 \0.001 \0.001
Total zeaxanthin
Dose (mg) 1.55 1.75
Cmax (lmol/L)
c, d 0.077 ± 0.032 \0.001 0.083 ± 0.038 \0.001 0.164
Cmax (increase from t = 0 h)(lmol/L)
d 0.018 ± 0.017 \0.001 0.028 ± 0.021 \0.001 0.009
Tmax (h) 17.5 ± 20.9 \0.001 19.4 ± 12.1 \0.001 0.595
C14h (increase from t = 0 h) (lmol/L)
d 0.003 ± 0.014 0.225 0.008 ± 0.026 0.046 0.315
AUC(0–72h) (lmol h/L)
c, d 4.110 ± 1.785 \0.001 4.414 ± 2.321 \0.001 0.175
all-E-zeaxanthin
Cmax (lmol/L)
c, d 0.060 ± 0.024 \0.001 0.067 ± 0.031 \0.001 0.032
Cmax (increase from t = 0 h) (lmol/L)
d 0.013 ± 0.012 \0.001 0.023 ± 0.015 \0.001 \0.001
Tmax (h) 19.4 ± 21.0 \0.001 20.4 ± 12.1 \0.001 0.757
C14h (increase from t = 0 h) (lmol/L)
d 0.003 ± 0.010 0.057 0.008 ± 0.019 0.006 0.135
AUC(0–72h) (lmol h/L)
c, d 3.253 ± 1.337 \0.001 3.569 ± 1.903 \0.001 0.082
All values are expressed as mean with standard deviation
a Within group comparisons for the difference from zero were made using t tests. Probability values p \ 0.05 are statistically significant
b Between group comparisons were made using analysis of variance (ANOVA). Probability values p \ 0.05 are statistically significant
c Data were log transformed prior to statistical comparisons
d Zeaxanthin values for SMB were adjusted (multiplied by the factor (1.55/1.75)) to correct for the difference in dose of zeaxanthin between the
two study products
Table 3 Lutein and zeaxanthin bioavailability measured by AUC (lmol h/L) in plasma over 672 h after a single dose of AMB or SMB
AMB (n = 47) p valuea SMB (n = 48b) p valuea p valuec
Total lutein 120.8 ± 47.4 \0.001 162.8 ± 70.2 \0.001 \0.001
all-E-lutein 102.7 ± 41.1 \0.001 139.1 ± 63.3 \0.001 \0.001
Total zeaxanthind 40.3 ± 22.3 \0.001 38.4 ± 28.6 \0.001 0.459
all-E-zeaxanthind 32.4 ± 17.5 \0.001 30.9 ± 24.4 \0.001 0.396
All values are expressed as mean with standard deviation
a Within group comparisons for the difference from zero were made using t tests. Probability values p \ 0.05 are statistically significant
b One subject withdrew prior to the 672 h blood collection in their first dosing period (SMB). This subjects’ 672 h values were imputed using the
subjects’ pre-dose values (t = 0 h) for the missing data and the subject included in the analysis of the 672 h bioavailability for SMB
c Between group comparisons were made using analysis of variance (ANOVA). Probability values p \ 0.05 are statistically significant
d Zeaxanthin values for SMB were adjusted (multiplied by the factor (1.55/1.75)) to correct for the difference in dose of zeaxanthin between the
two study products
Eur J Nutr (2013) 52:1381–1391 1387
123
14 h from pre-dose in total zeaxanthin and a 16.3 %
increase in its principle isomer all-E-zeaxanthin, while
AMB showed an 5.1 % increase at 14 h from pre-dose in
total zeaxanthin and a 6.4 % increase in all-E-zeaxanthin.
Bioavailability of total and all-E-zeaxanthin in response to
AMB exhibited an absorption pattern limited to the first
24 h post-test article administration followed by a decrease
in blood concentrations below pre-dose levels. There was
an increase in plasma concentrations after 72 h continuing
through 672 h, perhaps suggesting a dietary influence.
However, SMB demonstrated a plasma zeaxanthin profile
that was maintained for greater than 72 h post-
supplementation and, similar to AMB, the profile showed
an increase in plasma values from 168 to 672 h. The serum
profiles of all-E-lutein and all-E-zeaxanthin were similar to
and closely followed the profiles of total lutein and total
zeaxanthin suggesting that all-E-lutein and all-E-zeaxan-
thin are the predominant isomers in the plasma. The profile
for the 72 h total lutein mimicked that of total zeaxanthin
during the initial 72 h in response to SMB with an initial
peak seen after 14 h and a second peak of lesser magnitude
around 32 h.
It is interesting that this second peak appears in the
profiles of both zeaxanthin (Fig. 4) as well as lutein
Fig. 2 Mean plasma total lutein
(solid line) and all-E-lutein
(dotted line) concentrations pre-
dose and over a 72-h period
following administration of
AMB (triangle) or SMB (circle)
each containing, respectively,
20.9 or 20.4 mg of lutein and
1.55 or 1.75 mg of zeaxanthin.
Data are expressed as
mean ± SEM
Fig. 3 Mean plasma total lutein
(solid line) and all-E-lutein
(dotted line) concentrations pre-
dose and over a 672-h period
following administration of
AMB (triangle) or SMB (circle)
each containing, respectively,
20.9 or 20.4 mg of lutein and
1.55 or 1.75 mg of zeaxanthin.
Data are expressed as
mean ± SEM
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(Fig. 2) and reaches maximum values after approximately
32 h in each case. The appearance of this second peak was
not observed by Yao et al. [19] who measured lutein in the
bloodstream of humans using a 13C tracer technique.
However, the latter study included only one measurement
of plasma lutein in the interval between 16 and 48 h,
namely at 24 h. The lack of additional measurements
within this timeframe when the second peak was observed
in the present study, probably accounts for the differences
observed. This second peak, visible for SMB only, could be
explained by the general characteristics of carotenoid
absorption. After ingestion of a single dose of b-carotene, a
similar second plasma concentration peak has been repor-
ted [20]. The authors have concluded that the early rise in
circulating b-carotene concentrations is caused by the
intestinal input, whereas hepatic secretion is the source of
Fig. 4 Mean plasma total zeaxanthin (solid line) and all-E-zeaxan-
thin (dotted line) concentrations pre-dose and over a 72-h period
following administration of AMB (triangle) or SMB (circle) each
containing, respectively, 20.9 or 20.4 mg of lutein and 1.55 or
1.75 mg of zeaxanthin. Data are expressed as mean ± SEM
Fig. 5 Mean plasma total
zeaxanthin (solid line) and
all-E-zeaxanthin (dotted line)
concentrations pre-dose and
over a 672-h period following
administration of AMB
(triangle) or SMB (circle) each
containing, respectively, 20.9 or
20.4 mg of lutein and 1.55 or
1.75 mg of zeaxanthin. Data are
expressed as mean ± SEM
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later increases. It is likely that the xanthophylls behave
similar to beta-carotene. Additionally, the second peak may
arise from further release of xanthophylls into the circu-
lation via newly synthesized chylomicrons from the intes-
tine induced by a subsequent meal (fat). Such distinctive
profiles in plasma response were not seen with AMB.
Statistical analysis of pharmacokinetic parameters
demonstrated that total and all-E-lutein were significantly
increased in the plasma in response to SMB. Mean total
lutein and all-E-lutein AUC(0–72h) were significantly
increased (p \ 0.001) in response to SMB as compared to
AMB. Mean maximum plasma total lutein and all-E-lutein
concentrations (Cmax) were significantly (p \ 0.001)
higher in subjects after administration of SMB. Though the
time to reach maximum concentration (Tmax) was not sig-
nificantly different between test products as measured by
total or all-E-lutein, there was a faster response to SMB for
total lutein and all-E-lutein as compared to AMB.
Numerous studies in the literature attest to the impor-
tance of the role of lutein and zeaxanthin in the prevention
of age-related eye diseases in high-risk populations. In the
course of the Lutein Antioxidant Supplementation Trial
(LAST), a double-blind, placebo-controlled trial in 90
patients with atrophic AMD, 10 mg of lutein was supple-
mented for 1 year. Along with increases in macular pig-
ment optical density, there was net improvement in several
visual function parameters (glare and contrast sensitivity,
visual acuity) in addition to a reversal of the symptoms of
AMD indicating a potentially preventative activity against
the development of AMD [21]. Nutritional studies corre-
lating the effects of high dietary intake of antioxidants with
protection against AMD reported that higher intakes of
carotenoids were associated with a reduced risk of exuda-
tive neovascular macular degeneration [22]. The carote-
noids lutein and zeaxanthin obtained principally from dark
green, leafy vegetables such as spinach, kale, collard
greens, mustard greens, and turnip greens were most
strongly associated with reduced risk of AMD. Addition-
ally, several prospective studies have reported that higher
intakes of lutein and zeaxanthin were associated with
decreased risk of cataracts [23]. After a 10-year follow-up,
women consuming the most lutein and zeaxanthin had an
18 % lower risk of developing cataracts than those who
consumed the least. More recently, older women with high
dietary concentrations of lutein and zeaxanthin have been
associated with decreased prevalence of nuclear cataracts
[24].
Knowledge relating to the formulation of supplements
and the pharmacokinetics of lutein absorption is critical to
a better understanding of plasma bioavailability of these
carotenoids. A variation of lutein from different food
sources [25, 26] and the vast individual variation in mac-
ular accumulation and its variance in target populations
[11] make it important that bioavailability studies research
the pharmacokinetics of supplements prior to the imple-
mentation of long-term clinical trials. Furthermore, due to
the fact that the polarities of lutein and zeaxanthin are
similar, most researchers report combined values for lutein
and zeaxanthin when reporting results. In the current study,
plasma samples were analyzed for the xanthophylls lutein
and zeaxanthin and their all-E-isomers thereby providing a
more comprehensive assessment of the availability of the
prevalent isomer in the plasma. Thus, the data generated
from this study provide clear kinetics of the two materials
evaluated after a single dose and allowed for the assess-
ment of the bioavailability of the materials. In light of the
high prevalence of eye disease in aging populations and
the impact of lutein and zeaxanthin in its prevention, the
results of the current study are significant.
Of the subjects enrolled into the current study, 87.5 %
were White, while 4.2 % were Asian–Oriental, 4.2 %
Black, and 4.2 % East Indian; 14.6 % of enrolled subjects
were current smokers. Pooled data from several studies
have identified that there is a strong age-related increase in
AMD in people of European descent with significant
increases in rates in both men and women older than
80 years of age [27].
In this population of subjects, a single dose of SMB
resulted in a 126.0 % increase in total plasma lutein and a
144.1 % increase from pre-dose in its principle isomer
all-E-lutein within the first 14 h as well as a significant
increase in AUC(0–72h) for total plasma lutein, all-E-lutein,
total zeaxanthin and all-E-zeaxanthin and AUC(0–672h) for
total plasma lutein and all-E-lutein. AUC values were
significantly higher than those reached after AMB admin-
istration, demonstrating the superiority of SMB over AMB.
Additionally, the data gathered should be helpful to future
research and clinical studies in relation to determining
optimal dosing regimens and anticipated blood concentra-
tions of lutein and zeaxanthin from the dosages chosen.
Although case–control studies suggest a combined dose
of 6 mg of lutein and zeaxanthin per day for reducing the
risk of AMD, the average North American ingests only
1–2 mg of lutein daily from their diet [22, 28]. This may
lead to a deficit of these important carotenoids. With the
dramatic increase in age-related eye diseases, it becomes
very important to more thoroughly understand the issues
associated with the bioavailability of lutein and zeaxanthin
supplement formulations and their potential impact upon
target populations.
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